These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Chevet E; Fessart D; Delom F; Mulot A; Vojtesek B; Hrstka R; Murray E; Gray T; Hupp T Oncogene; 2013 May; 32(20):2499-509. PubMed ID: 22945652 [TBL] [Abstract][Full Text] [Related]
4. A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. Maslon MM; Hrstka R; Vojtesek B; Hupp TR J Mol Biol; 2010 Dec; 404(3):418-38. PubMed ID: 20888340 [TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry analysis of the oxidation states of the pro-oncogenic protein anterior gradient-2 reveals covalent dimerization via an intermolecular disulphide bond. Clarke DJ; Murray E; Faktor J; Mohtar A; Vojtesek B; MacKay CL; Smith PL; Hupp TR Biochim Biophys Acta; 2016 May; 1864(5):551-61. PubMed ID: 26876500 [TBL] [Abstract][Full Text] [Related]
6. Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration. Li Z; Wu Z; Chen H; Zhu Q; Gao G; Hu L; Negi H; Kamle S; Li D Med Oncol; 2015 Jun; 32(6):577. PubMed ID: 25956506 [TBL] [Abstract][Full Text] [Related]
7. TSG101, a tumor susceptibility gene, bidirectionally modulates cell invasion through regulating MMP-9 mRNA expression. Sai XB; Makiyama T; Sakane H; Horii Y; Hiraishi H; Shirataki H BMC Cancer; 2015 Nov; 15():933. PubMed ID: 26608825 [TBL] [Abstract][Full Text] [Related]
8. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Li L; Liao J; Ruland J; Mak TW; Cohen SN Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1619-24. PubMed ID: 11172000 [TBL] [Abstract][Full Text] [Related]
9. TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer. Liu F; Yu Y; Jin Y; Fu S Mol Biol Rep; 2010 Jul; 37(6):2829-38. PubMed ID: 19787439 [TBL] [Abstract][Full Text] [Related]
10. Regulation of AGR2 expression via 3'UTR shortening. Matoulkova E; Sommerova L; Pastorek M; Vojtesek B; Hrstka R Exp Cell Res; 2017 Jul; 356(1):40-47. PubMed ID: 28408318 [TBL] [Abstract][Full Text] [Related]
11. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition. Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396 [TBL] [Abstract][Full Text] [Related]
12. The role of AGR2 and AGR3 in cancer: similar but not identical. Obacz J; Takacova M; Brychtova V; Dobes P; Pastorekova S; Vojtesek B; Hrstka R Eur J Cell Biol; 2015; 94(3-4):139-47. PubMed ID: 25666661 [TBL] [Abstract][Full Text] [Related]
13. Extracellular AGR2 triggers lung tumour cell proliferation through repression of p21 Fessart D; de Barbeyrac C; Boutin I; Grenier T; Richard E; Begueret H; Bernard D; Chevet E; Robert J; Delom F Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118920. PubMed ID: 33278424 [TBL] [Abstract][Full Text] [Related]
14. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. de Belle I; Huang RP; Fan Y; Liu C; Mercola D; Adamson ED Oncogene; 1999 Jun; 18(24):3633-42. PubMed ID: 10380885 [TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic PML function in TGF-beta signalling. Lin HK; Bergmann S; Pandolfi PP Nature; 2004 Sep; 431(7005):205-11. PubMed ID: 15356634 [TBL] [Abstract][Full Text] [Related]
16. TSG101 interacts with the androgen receptor and attenuates its expression through the endosome/lysosome pathway. Lin YM; Chu PH; Ouyang P Biochem Biophys Res Commun; 2018 Sep; 503(1):157-164. PubMed ID: 29859188 [TBL] [Abstract][Full Text] [Related]
17. 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Ambolet-Camoit A; Bui LC; Pierre S; Chevallier A; Marchand A; Coumoul X; Garlatti M; Andreau K; Barouki R; Aggerbeck M Toxicol Sci; 2010 Jun; 115(2):501-12. PubMed ID: 20299546 [TBL] [Abstract][Full Text] [Related]